Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023

SELL
$1.9 - $2.27 $84,187 - $100,581
-44,309 Reduced 22.15%
155,691 $316,000
Q4 2021

Feb 14, 2022

BUY
$3.11 - $4.61 $622,000 - $922,000
200,000 New
200,000 $778,000

Others Institutions Holding ABUS

About Arbutus Biopharma Corp


  • Ticker ABUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 149,951,008
  • Market Cap $528M
  • Description
  • Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...
More about ABUS
Track This Portfolio

Track Kepos Capital LP Portfolio

Follow Kepos Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kepos Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Kepos Capital LP with notifications on news.